title: Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.
abstract: Oxaliplatin (OxP) has been used in combination therapy with gemcitabine for the treatment of pancreatic cancer (PC), but the beneficial effect was marginal, which is believed to be due to de novo and acquired drug resistance of PC. Here, we report our in vitro and in vivo preclinical evidence in support of chemosensitization of drug-resistant cells by a nontoxic chemopreventive agent (genistein). Genistein pretreatment together with low concentration of OxP showed significant reduction in cell viability and colony formation concomitant with increased apoptosis (p < 0.01), which was highly synergistic. Drug resistance of PC is allegedly linked with both constitutive and OxP-induced activation of NF-κB, and we found that inactivation of (nuclear factor kappa B) NF-κB by genistein before treatment of cells with OxP was required for cell killing, which was consistent with the downregulation of NF-κB and its downstream antiapoptotic genes (Bcl-2, XIAPs and survivin). Most importantly, our in vivo experiments using orthotopic mouse model showed significant reduction in tumor size (p < 0.01) and reduction of locoregional lymph node metastasis by combination treatment. These results were also consistent with inactivation of NF-κB and the downregulation of NF-κB downstream genes, decreased proliferation marker (Ki-67) and increased apoptosis (TUNEL) in tumor remnants, all of which was consistent with in vitro findings. From these results, we conclude that genistein sensitizes drug-resistant PC to OxP, which is mechanistically linked with inactivation of NF-κB signaling, resulting in greater antitumor effects, and thus our data suggest that this approach could be useful in improving the treatment outcome for patients diagnosed with PC.
authors.affiliation: Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Wayne State University, Detroit, MI, USA.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Banerjee
authors.forename: Dejuan
authors.initials: D
authors.lastname: Kong
authors.forename: Asfar S
authors.initials: AS
authors.lastname: Azmi
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Wang
authors.forename: Aamir
authors.initials: A
authors.lastname: Ahmad
authors.forename: Seema
authors.initials: S
authors.lastname: Sethi
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D024202:Electrophoretic Mobility Shift Assay; D005260:Female; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D051379:Mice; D008813:Mice, Inbred ICR; D016513:Mice, SCID; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000473:pathology*; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: Pancreas. 2004 May;28(4):e90-5
references.pmid: 15097869
references.citation: Expert Opin Pharmacother. 2007 Nov;8(16):2719-27
references.pmid: 17956194
references.citation: Cancer Res. 2005 Oct 1;65(19):9064-72
references.pmid: 16204081
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Cancer Res. 2009 Jul 1;69(13):5575-83
references.pmid: 19549912
references.citation: Clin Cancer Res. 2008 Dec 15;14(24):8143-51
references.pmid: 19088029
references.citation: Anticancer Drugs. 2009 Sep;20(8):713-22
references.pmid: 19617819
references.citation: Eur J Nutr. 2001 Aug;40(4):135-46
references.pmid: 11905954
references.citation: Clin Cancer Res. 2009 Oct 15;15(20):6367-77
references.pmid: 19808866
references.citation: Int J Cancer. 2007 Feb 15;120(4):906-17
references.pmid: 17131310
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2712-25
references.pmid: 19414669
references.citation: Cancer. 2009 May 15;115(10):2165-76
references.pmid: 19288574
references.citation: J Chemother. 2005 Feb;17(1):86-95
references.pmid: 15828450
references.citation: Nutr Cancer. 2009;61(5):587-97
references.pmid: 19838932
references.citation: Dig Dis Sci. 2009 Jan;54(1):89-96
references.pmid: 18594980
references.citation: Cancer Res. 2009 Jul 1;69(13):5592-600
references.pmid: 19531648
references.citation: Cancer Metastasis Rev. 2002;21(3-4):265-80
references.pmid: 12549765
references.citation: Int J Cancer. 2003 Jul 20;105(6):735-46
references.pmid: 12767057
references.citation: Cancer Lett. 2009 Jun 18;278(2):201-209
references.pmid: 19231069
references.citation: Cancer Treat Rev. 2009 Nov;35(7):597-607
references.pmid: 19660870
references.citation: Semin Oncol. 2007 Aug;34(4):347-53
references.pmid: 17674963
references.citation: Drugs. 2006;66(8):1059-72
references.pmid: 16789792
references.citation: Kidney Int. 2008 Dec;74(12):1538-47
references.pmid: 18716605
references.citation: Biochem Biophys Res Commun. 2005 Jul 1;332(2):433-40
references.pmid: 15896711
references.citation: Cancer Lett. 2008 Oct 8;269(2):226-42
references.pmid: 18492603
references.citation: Recent Results Cancer Res. 2008;177:151-64
references.pmid: 18084957
references.citation: Cancer Invest. 2003;21(5):744-57
references.pmid: 14628433
references.citation: Mol Cancer Res. 2010 Jan;8(1):24-34
references.pmid: 20068070
references.citation: Biochem Pharmacol. 2004 Jun 1;67(11):2031-8
references.pmid: 15135300
references.citation: Invest New Drugs. 2010 Dec;28(6):812-24
references.pmid: 19777160
references.citation: In Vivo. 2005 Jan-Feb;19(1):61-7
references.pmid: 15796156
references.citation: Semin Oncol. 2007 Apr;34(2 Suppl 1):S25-30
references.pmid: 17449349
references.citation: Cancer Res. 2006 Nov 1;66(21):10553-9
references.pmid: 17079479
references.citation: Cancer Lett. 2010 Jun 1;292(1):54-63
references.pmid: 19959278
references.citation: Cancer Invest. 2005;23(1):9-12
references.pmid: 15779862
references.citation: Cancer Treat Rev. 2009 Dec;35(8):676-84
references.pmid: 19758760
references.citation: Cancer Sci. 2003 May;94(5):467-72
references.pmid: 12824895
references.citation: Oncogene. 2003 May 22;22(21):3243-51
references.pmid: 12761494
references.citation: Cancer Res. 2004 Jun 15;64(12):4346-52
references.pmid: 15205350
references.citation: Cancer Lett. 2010 May 1;291(1):90-8
references.pmid: 19880242